Genmab — August 2019
-
Revenue
We expect our 2019 revenue to be approximately DKK 4,800 million, an increase of DKK 200 million compared to the previous guidance. Our projected revenue for 2019 primarily consists of DARZALEX royalties of DKK 2,885 million, an increase of DKK 200 million from the previous guidance due to positive impact of USD/DKK exchange rates movements. The DARZALEX royalties are based on estimated net sales of USD 3.0 billion in 2019. We continue to project DARZALEX milestones of approximately DKK -
KKJ se side 18 der har du de data
-
Og analytikerne havde i forvejen indregnet den aktuelle dollars kurs i deres estimater
-
-
Udgifterne stiger til 1,5 mia her i 2. Halvår. Så når vi op omkring 3,5 mia næste år
-
SB det nævner de ikke umiddelbart. Men regner med det er tæt på aktuel kurs
-
Mht udgifter: derfor er jo også giftigt hvis 3 mia ikke nås
-
SB husk du skal trække 1 mia fra næste år på oms i forhold til i år i relation til de 2 store salgs milestones....
-
Pointen er blot at den underliggende vækst bliver markant lavere fordi udgifter stiger hurtigt. Og jeg venter stadig at se hvad de mange ekstra penge skal bruges til. Det er jokeren
-
Hvad ender overskud på hvis omsætning kun når 2,9 mia?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind